Teva stock faces emrusolmin trial setback as study is halted

Teva Pharmaceuticals will discontinue the Phase 2 TOPAS-MSA study of emrusolmin in adults with multiple system atrophy after an interim analysis found a low probability of meeting the trial's primary efficacy endpoint. The company announced the decision on Monday, November 2, 2026, in a Teva press release.

Interim review ends Phase 2 study

The independent data monitoring committee recommended discontinuation after a prespecified predictive futility analysis met the predefined stopping criterion. Teva said the review was not the study's final efficacy analysis and identified no safety concerns.

TOPAS-MSA was designed as a randomized, double-blind, placebo-controlled study of emrusolmin in multiple system atrophy, a rare neurodegenerative disorder. The trial planned to enroll approximately 350 participants, who would receive emrusolmin 300 milligrams or placebo for approximately 48 weeks, followed by a four-week follow-up.

Broader program remains open

The decision applies to TOPAS-MSA and does not represent a final decision on the broader emrusolmin program. Teva, which is developing the oral drug with MODAG GmbH, plans to complete a comprehensive analysis of the study and review available data from a separate open-label extension study.

The company said it intends to share the TOPAS-MSA findings with the scientific community after completing that analysis. For investors, the next assessment point is whether the additional evidence can support a further development path despite the failed interim efficacy outlook.

Teva is scheduled to host its third-quarter 2026 earnings call on Tuesday, November 3, 2026, at 8:00 a.m. Eastern Time, according to the release.

US equities remain the broader market backdrop for Teva stock, with the S&P 500 as the relevant benchmark.

Find more news and analyses on Teva stock.